Company
Headquarters: Taoyuan City, Taiwan
TW$22.00 Billion
TWD as of Jan. 1, 2025
US$670.2 Million
Company | Market Cap (USD) |
---|---|
Lilly | $689.42 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $487.54 B |
Johnson & Johnson | $353.05 B |
AbbVie | $301.60 B |
Grape King Bio Ltd produces and sells pharmaceutical preparations, patent medicines, liquid tonics, drinks, and healthy foods in Taiwan, China, and internationally. It operates through Multi-Level Marketing, Distributors, and Original Design Manufacturer/Original Equipment Manufacturer (ODM/OEM) segments. The company offers mushroom mycelium products, such as ganoderma lucidum, agaricus blazei, antrodia cinnamomea, cordyceps sinensis, and coriolus versicolor; probiotics, including enterococcus, bifidobacterium, lactobacillus, pediococcus, streptococcus, saccharomyces, and clostridium; and enzymes. It also provides OEM, ODM, formulation design, research and development, and raw material supply services. The company was founded in 1969 and is headquartered in Taoyuan, Taiwan.
Grape King Bio Ltd has the following listings and related stock indices.
Stock: TWSE: 1707 wb_incandescent